ArticleSchizophrenia bulletin2026
C-Reactive Protein Levels and Elevations in Schizophrenia: The Central Role of Body Mass Index.
Article in Schizophrenia bulletin, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundElevated levels of C-reactive protein (CRP) are consistently observed in individuals with schizophrenia. However, the extent to which this elevation is attributable to body mass index (BMI), demographic differences, and comorbid medical conditions remains unclear. STUDY
methodsCRP was measured in blood plasma from 772 individuals (479 schizophrenia, 293 controls). Group differences in log10-transformed and binary CRP (≥3 μg/mL) were examined across 5 sequentially adjusted regression models progressively incorporating sex, age, maternal education, cigarette smoking, race, and BMI. Within schizophrenia, 44 comorbidity, clinical, and medication variables were each tested against both CRP quantitative and categorical outcomes using the 5-model framework, with multiple comparison correction applied to fully adjusted models. STUDY
resultsCompared to controls, schizophrenia was associated with significantly higher CRP in models incorporating sex, age, maternal education, race and smoking (all P < .001). The addition of BMI substantially attenuated these group differences, although associations remained statistically significant. Within schizophrenia, BMI was the dominant predictor of CRP levels, accounting for a substantial amount of the CRP variance (β = +0.031/unit, P < .001). Of 20 variables significant in unadjusted models, only 7 remained significant after full adjustment and multiple comparison correction: acne vulgaris, gastrointestinal reflux, urinary tract infections, migraine, autoimmune disorders, clozapine, and antidepressant use.
conclusionsCRP elevation in schizophrenia is substantially attenuated by BMI adjustment but remains significantly different from unaffected controls across continuous and binary outcomes in fully adjusted models. BMI and other relevant covariates should be incorporated into schizophrenia studies employing CRP as an inflammatory indicator.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.